DEXCOM INC 8-K

What Happened
Dexcom, Inc. announced that President and CEO Jake Leach will present preliminary, unaudited financial results for the fourth quarter of 2025 and fiscal year 2025, and provide an initial financial outlook for fiscal 2026, at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026 (10:30 a.m. ET). The preliminary results and guidance were issued in a press release on January 12, 2026 and are subject to finalization in Dexcom’s Annual Report on Form 10‑K for the year ended December 31, 2025. The filing emphasizes that the presentation and releases contain forward-looking statements about revenue, Non‑GAAP gross profit margin, Non‑GAAP operating margin, and other strategic matters.

Key Details

• CEO Jake Leach’s presentation occurred at the J.P. Morgan conference on January 12, 2026 (10:30 a.m. ET).
• Dexcom issued a press release on January 12, 2026 with preliminary unaudited Q4 and FY2025 results and initial FY2026 guidance (Exhibit 99.1).
• A business update press release dated January 7, 2026 is also attached to the filing (Exhibit 99.2).
• The reported results and guidance are preliminary, unaudited and subject to change when finalized in Dexcom’s Form 10‑K; the filing reiterates that forward‑looking statements are subject to risks described in prior SEC filings.

Why It Matters
Preliminary quarterly and full‑year results plus an initial outlook for 2026 can materially affect investor expectations for revenue and profitability. Because the numbers are unaudited and subject to finalization in the Form 10‑K, investors should treat the figures as provisional and review the forthcoming Form 10‑K and the company’s disclosed risk factors before making investment decisions.